Compare FRHC & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRHC | RDY |
|---|---|---|
| Founded | N/A | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 11.6B |
| IPO Year | 1996 | 2001 |
| Metric | FRHC | RDY |
|---|---|---|
| Price | $139.99 | $13.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.90 |
| AVG Volume (30 Days) | 73.2K | ★ 2.5M |
| Earning Date | 06-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $2,050,527,000.00 | N/A |
| Revenue This Year | N/A | $7.72 |
| Revenue Next Year | N/A | $3.50 |
| P/E Ratio | $59.44 | ★ $18.67 |
| Revenue Growth | ★ 25.41 | N/A |
| 52 Week Low | $107.98 | $12.77 |
| 52 Week High | $194.01 | $16.17 |
| Indicator | FRHC | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 49.39 |
| Support Level | $138.57 | $12.90 |
| Resistance Level | $177.93 | $14.21 |
| Average True Range (ATR) | 5.71 | 0.24 |
| MACD | -2.20 | 0.02 |
| Stochastic Oscillator | 14.69 | 48.95 |
Freedom Holding Corp is a holding company with its subsidiary it is engaged in securities brokerage, securities dealing for customers and account, market-making activities, investment research, investment counseling, investment banking services, retail and commercial banking, insurance products, payment services, and information processing services. It acts as a professional participant through its subsidiaries on the Kazakhstan Stock Exchange (KASE), Moscow Exchange (MOEX), Saint-Petersburg Exchange (SPB), the Ukrainian Exchange, the Uzbek Republican Currency Exchange (UZCE), and the Republican Stock Exchange of Tashkent (UZSE). Its segments are Brokerage, Banking, Insurance, and Others.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.